Hexarelin dosage: Frequently asked questions

Switch to once-daily dosing at 100–150mcg or alternate hexarelin with a different GHS-R1a ligand (GHRP-2 or ipamorelin) on a weekly rotation. Continuous three-times-daily hexarelin dosing for 12 weeks will produce severe desensitization by week 4–6, rendering the peptide nearly ineffective for the final two-thirds of the study. Alternating ligands or reducing frequency maintains measurable GH elevation throughout the timeline, though peak amplitude will still decline 20–30% from baseline by month three.

Increase to 150–200mcg for the next administration and reassess response. Some research models (older animals, obese models, metabolically compromised subjects) show reduced GHS-R1a sensitivity and require higher doses to achieve comparable GH pulses. If 200mcg still produces suboptimal response, the issue is likely receptor density or pituitary GH reserves rather than dosing. Further escalation above 250mcg rarely improves output and significantly elevates cortisol.

Reduce injection frequency to once daily or implement a 5-days-on, 2-days-off cycle immediately. GH response decline after two weeks signals GHS-R1a downregulation. The pituitary is producing fewer receptors in response to sustained hexarelin exposure. Increasing dose at this stage accelerates desensitization rather than restoring output. The recovery period (2 days off per week) allows receptor expression to normalize, typically restoring 70–85% of initial GH pulse amplitude within one cycle.

Administer the dose as scheduled but expect attenuated GH response. Elevated insulin and blood glucose suppress pituitary GH secretion through inhibition of GHRH neurons and direct action on somatotroph cells. The same hexarelin dose given 30 minutes after a carbohydrate-rich meal may produce 40–60% less growth hormone release than identical dosing after a 3-hour fast. This doesn't indicate peptide degradation or protocol failure; it reflects the physiological interaction between nutrient signaling and the growth hormone axis. For acute single-dose studies measuring peak GH, fed-state administration invalidates the data. For chronic protocols measuring cumulative effects like IGF-1 elevation or body composition changes, occasional fed-state doses reduce consistency but don't eliminate the overall effect. Though standardizing administration timing improves data quality and reduces intra-subject variability.

Skip the missed dose and resume the protocol at the next scheduled administration. Do not double-dose to compensate. Growth hormone secretagogues operate through pulsatile receptor activation; administering a double dose does not produce double the GH release due to receptor saturation kinetics. Missing a single dose in a twice-daily protocol creates a 24-hour gap instead of the intended 12-hour interval, which may slightly alter the data point for that day but does not compromise the overall study integrity. Document the missed dose as a protocol deviation in study records. If multiple doses are missed (3 or more consecutive administrations), consider whether the study timeline should be extended to accumulate the originally planned number of exposure days, or whether the reduced cumulative exposure becomes a study limitation addressed in data analysis.

This is expected receptor desensitization, not product failure. Implement a washout period of 7–14 days with no hexarelin administration, allowing GHS-R1a receptors to upregulate and resensitize. Upon resuming administration, initial doses will produce GH responses comparable to early-protocol levels. The European Journal of Endocrinology documented this recovery pattern in a study where subjects who took a 2-week break after 12 weeks of daily hexarelin returned to 85% of their baseline GH response magnitude. Alternatively, transition to an intermittent protocol (5 days on, 2 days off) that incorporates regular receptor recovery windows into the ongoing study design. Some research groups reduce dose during weeks 9–12 (stepping down to 100–150mcg per administration) to maintain receptor engagement without full saturation, though this approach requires careful GH monitoring to confirm therapeutic thresholds are still being met.

Refrigerate immediately and continue using the vial if the excursion was a single event lasting fewer than 6 hours. Peptide degradation is temperature- and time-dependent. A 4-hour room-temperature exposure causes minimal structural damage, though potency may decrease by 3–8% depending on ambient temperature. Repeated temperature cycling, however, is cumulative and irreversible. If a vial has been left out multiple times or for durations exceeding 8 hours, consider it compromised and prepare a fresh vial. There is no reliable at-home test for peptide integrity. Solutions may appear clear and colorless even after significant denaturation has occurred. The conservative approach: if cold chain integrity is uncertain, replace the vial and improve storage protocols going forward. Real Peptides includes temperature stability documentation with each shipment, specifying maximum acceptable excursion parameters based on the specific peptide sequence.

If you miss a dose by less than 4 hours, administer the missed dose immediately unless it's close to your next scheduled dose.[1] Do not double dose to make up for missed administrations, as this increases hypoglycemia and side effect risk. Missing occasional doses (1-2 per week) minimally impacts therapeutic outcomes, but frequent missed doses can reduce treatment efficacy by 20-30%.

Discard it immediately. Cloudiness indicates protein aggregation or bacterial contamination. Neither is reversible, and injecting degraded peptide achieves nothing. Hexarelin's 6-amino-acid structure is fragile; temperature excursions, light exposure, or contamination during reconstitution all cause irreversible denaturation. If cloudiness appears before 30 days, review your reconstitution technique: did you inject bacteriostatic water down the vial wall gently, or did you spray it directly onto the lyophilised cake? Direct spray causes foaming and accelerates degradation.

Discard it immediately. Properly reconstituted Hexarelin should be completely clear and colorless. Cloudiness indicates peptide aggregation, bacterial contamination, or reconstitution with incorrect solvent. All of which render the compound unusable. Aggregated peptides can't bind GHS-R1a receptors effectively and may trigger immune responses that confound research outcomes.

Discard the solution and reconstitute a fresh aliquot. Peptide degradation at room temperature is irreversible and unpredictable. HPLC analysis of room-temperature-exposed hexarelin shows 15–25% formation of oxidised and deamidated degradation products within 48 hours, creating a mixed solution where intact peptide concentration is unknown. Using degraded peptide introduces uncontrolled variables that invalidate dose-response relationships and compromise reproducibility across experimental timepoints.

Administer the next dose in a fasted state and resume the protocol. Don't double-dose to compensate. Elevated insulin from food intake suppresses GH secretion by 60–80%, meaning the peptide still binds to ghrelin receptors but the downstream hormonal cascade is blunted to near-baseline levels. Research shows that even small amounts of protein or carbohydrate (as little as 20–30 grams) within two hours of administration reduce peak GH levels by more than half. The compound isn't wasted. It's metabolized and cleared. But the fat-mobilizing effect is negligible.

Administer 200mcg as a single morning dose and document the modification in methods. This dosing will produce measurable but reduced cardioprotection (18–22% infarct reduction versus 38–44% with twice-daily). The mechanism remains active but receptor occupancy gaps during the 20-hour interdose interval diminish cumulative pathway activation. If twice-daily dosing becomes feasible mid-study, implement a 3-day washout before transitioning to avoid overlapping receptor dynamics that confound data interpretation.

Verify peptide identity and purity through third-party HPLC analysis before modifying the dosing protocol. Synthesis errors and mislabeling occur more frequently than dosing failures. If the peptide verifies as authentic hexarelin at ≥98% purity, evaluate injection timing relative to ischemia induction: cardioprotective preconditioning requires 3–7 days of hexarelin administration before ischemic insult. Acute administration (single dose immediately pre-ischemia) produces minimal protection because CD36-mediated pathway activation requires 48–72 hours to upregulate downstream effectors like heat shock proteins and antioxidant enzymes.

Reduce carbohydrate intake in the meal following the injection and ensure at least 90 minutes elapses between administration and food intake. While hexarelin binds to ghrelin receptors, it doesn't universally suppress appetite the way pharmaceutical ghrelin antagonists do. Some models experience transient hunger spikes 2–3 hours post-injection as blood glucose drops during the GH-induced lipolytic phase. This is distinct from the sustained appetite stimulation seen with GHRP-2 or MK-677. If hunger becomes unmanageable, split the daily dose into smaller, more frequent injections (e.g., four 75 mcg doses instead of three 100 mcg doses) to flatten the GH curve and reduce glucose fluctuations.

If the vial was at room temperature (18–25°C) for fewer than 12 hours, refrigerate it immediately and use it within 72 hours. Peptide degradation at that duration is minimal but measurable. If the exposure exceeded 12 hours or the temperature was above 25°C, discard the vial. Hexarelin is a synthetic hexapeptide vulnerable to conformational changes at elevated temperatures. Once the peptide chain denatures, re-cooling does not restore potency. Visual inspection is unreliable; degraded Hexarelin appears identical to active peptide. Temperature loggers or reconstitution in smaller volumes (to increase use frequency and reduce storage duration) prevent this scenario.

No. Resume the regular schedule at the standard dose and continue the protocol. Doubling a dose to 300–400 mcg doesn't recover the missed GH pulse and instead saturates ghrelin receptors without proportional benefit, while increasing the risk of transient side effects like flushing, dizziness, or cortisol elevation. Hexarelin's lipolytic effect is cumulative over weeks, not dependent on perfect adherence to every single dose. Missing one or two injections per week reduces total weekly GH secretion but doesn't negate fat loss outcomes if the overall protocol remains consistent.

Yes, but the reverse is harder to achieve. Doses above 200 mcg shift receptor binding away from cardiac CD36 toward pituitary GHS-R1a, so GH-focused protocols (300 mcg 3×/day) still provide some cardioprotection. Just not optimised. If your primary goal is cardiac outcomes, the twice-daily 100–150 mcg protocol delivers equivalent heart protection with lower cortisol elevation and less pituitary desensitisation. You can't fully separate the pathways, but you can weight the protocol toward one mechanism by controlling dose and frequency.

Skip that dose and wait until your next scheduled fasted injection window. Injecting within three hours of a meal containing carbohydrates or protein produces 40–60% lower GH response due to elevated insulin and glucose blocking somatotroph activation. The Hexarelin isn't wasted. It still binds receptors. But the GH pulse will be blunted significantly, and you've used a dose without achieving research-relevant elevation. If timing constraints prevent fasted dosing, move the injection to the next available fasted window rather than accepting suboptimal response.

This suggests receptor desensitization from chronic daily administration without breaks. Research protocols exceeding eight weeks often incorporate a 5–7 day washout every 4–6 weeks to restore receptor sensitivity. During the washout, basal GH secretion recovers and subsequent Hexarelin doses regain full potency. Continuous administration beyond 12 weeks without cycling produces progressively blunted responses in most models.